Richmond Pharmacology is excited to confirm our attendance at BioJapan 2025, Asia’s leading biotechnology partnering event, taking place in Yokohama from 8–10 October.

Representing Richmond at BioJapan 2025:

  • Dr Jörg Täubel, Chief Executive Officer
  • Stephen Wilkinson, Business Development Manager
  • Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
  • Minoru Takada, Japanese Business Development Executive

We look forward to connecting with global partners, sharing insights, and exploring opportunities in:

  • Early-phase trials for biologics and advanced therapies
  • UK–Japan collaboration in gene editing and RNA medicines
  • Regulatory strategy across Asia and Europe
  • Bridging studies and multi-regional trial design
  • Patient-centric and adaptive trial models

If you’re attending BioJapan 2025 and are looking to collaborate in translational research or clinical development, get in touch to arrange a meeting: info@richmondpharmacology.com

Learn more: BioJapan/ 再生医療JAPAN/ healthTECH JAPAN

Latest news

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event